Literature DB >> 9683948

Abnormalities in haemorheological factors and lipoprotein (a) in retinal vascular occlusion: implications for increased vascular risk.

P L Lip1, A D Blann, A F Jones, G Y Lip.   

Abstract

BACKGROUND: The pathogenesis of retinal vascular occlusion (RVO), which includes patients with retinal vein or artery occlusions, may be associated with abnormalities of rheology and coagulation. These abnormalities have previously been linked with an increased risk of cardiovascular disease and stroke. AIM, PATIENTS AND METHODS: To investigate changes in haemorheological factors (plasma viscosity, haematocrit, haemoglobin, white cell count (WCC), plasma fibrinogen (CLAUSS), soluble adhesion molecule P-selectin (associated with platelet activity and atherosclerosis; ELISA), von Willebrand factor (vWf, an index of endothelial dysfunction; ELISA), fibrin D-dimer (ELISA), lipoprotein(a) (Lp(a), immunoturbidometric assay) and serum lipids, we conducted a cross-sectional case-controlled study of 49 patients (37 men; mean age 66.9 years, SD 12.1 years) with RVO; 34 patients had retinal vein occlusion, whilst 15 had retinal artery occlusion. Their results were compared with those in 36 healthy controls (21 men; mean age 63.7 years, SD 14.8 years).
RESULTS: Patients with retinal vein occlusion and retinal artery occlusion had higher systolic and diastolic blood pressures compared with controls (both p < 0.0001). These patients also had significantly elevated levels of plasma viscosity, haematocrit, haemoglobin, plasma fibrinogen, PAI, fibrin D-dimer and serum Lp(a) compared with controls. Apart from a reduction in blood pressure, there were no significant differences in the indices measured in patients with retinal vein occlusion when levels measured during their first and second visits were compared. In patients with retinal artery occlusion mean plasma PAI levels were significantly lower at visit 2 compared with visit 1. Plasma viscosity was significantly correlated with fibrinogen (r = 0.63, p < 0.001), systolic blood pressure (r = 0.33, p = 0.03) and cholesterol (r = 0.32, p = 0.04), while P-selectin was correlated with Lp(a) levels (r = 0.38, p = 0.03).
CONCLUSION: This study suggests that abnormalities in haemorheological factors, fibrinogen and Lp(a) are present in patients with retinal vein occlusion and retinal artery occlusion. These abnormalities appear to persist even at follow-up examination 4-6 weeks later. Abnormalities in haemorheological factors, fibrinogen and Lp(a) may have a role in the pathogenesis of retinal vein occlusion and retinal artery occlusion, perhaps acting synergistically with clinical risk factors such as blood pressure. In addition, as haemorheological factors, fibrinogen and Lp(a) are associated with vascular disease, these findings in patients with RVO may potentially contribute to an increased risk of cardiovascular disease and stroke.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9683948     DOI: 10.1038/eye.1998.58

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  10 in total

1.  Unnecessary clinical tests in ophthalmology.

Authors:  James J Augsburger
Journal:  Trans Am Ophthalmol Soc       Date:  2005

2.  Therapeutic potential of intravitreal pharmacotherapy in retinal vein occlusion.

Authors:  Marianne L Shahsuvaryan
Journal:  Int J Ophthalmol       Date:  2012-12-18       Impact factor: 1.779

3.  Plasma vascular endothelial growth factor, soluble VEGF receptor FLT-1, and von Willebrand factor in glaucoma.

Authors:  P L Lip; D C Felmeden; A D Blann; N Matheou; S Thakur; I A Cunliffe; G Y H Lip
Journal:  Br J Ophthalmol       Date:  2002-11       Impact factor: 4.638

4.  Is activated factor VII associated with retinal vein occlusion?

Authors:  S Kadayifçilar; D Ozatli; O Ozcebe; E C Sener
Journal:  Br J Ophthalmol       Date:  2001-10       Impact factor: 4.638

5.  Hemodilution therapy using automated erythrocytapheresis in central retinal vein occlusion: results of a multicenter randomized controlled study.

Authors:  Agnès Glacet-Bernard; Marielle Atassi; Christine Fardeau; Jean-Paul Romanet; Matthieu Tonini; John Conrath; Philippe Denis; Martine Mauget-Faÿsse; Gabriel Coscas; Gisèle Soubrane; Eric Souied
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-10-17       Impact factor: 3.117

6.  Prediction of proliferative diabetic retinopathy with hemoglobin level.

Authors:  Baqiyyah N Conway; Rachel G Miller; Ronald Klein; Trevor J Orchard
Journal:  Arch Ophthalmol       Date:  2009-11

Review 7.  Homocysteine, methylenetetrahydrofolate reductase C677T polymorphism, and risk of retinal vein occlusion: an updated meta-analysis.

Authors:  Dan Li; Minwen Zhou; Xiaoyan Peng; Huiyu Sun
Journal:  BMC Ophthalmol       Date:  2014-11-27       Impact factor: 2.209

8.  Alteration of plasma von Willebrand factor in the treatment of retinal vein occlusion with cystoid macular edema.

Authors:  Hiromasa Hirai; Mariko Yamashita; Masanori Matsumoto; Takeyuki Nishiyama; Daishi Wada; Naoko Okabe; Yutaro Mizusawa; Hironobu Jimura; Tetsuo Ueda; Nahoko Ogata
Journal:  PLoS One       Date:  2022-09-22       Impact factor: 3.752

9.  Platelet-Derived Procoagulant Microvesicles Are Elevated in Patients with Retinal Vein Occlusion (RVO).

Authors:  Adrianna Marcinkowska; Nina Wolska; Boguslawa Luzak; Slawomir Cisiecki; Karol Marcinkowski; Marcin Rozalski
Journal:  J Clin Med       Date:  2022-08-30       Impact factor: 4.964

10.  Protective effect of paraoxonase 1 gene variant L55M in retinal vein occlusion.

Authors:  Huseyin Ortak; Erkan Söğüt; Omer Ateş; Unal Erkorkmaz; Ismail Benli; Ali Akbas; Selim Demir; Hüseyin Ozyurt
Journal:  Mol Vis       Date:  2013-02-25       Impact factor: 2.367

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.